Treatment options for urinary incontinenceMedical management of urinary incontinence
Section snippets
Pharmacotherapy for urinary incontinence
When pharmacotherapy is under consideration, one must identify the indication for the agent or agents being advocated. This step is particularly important in treating urinary incontinence because each of the several types of this disorder requires a different drug category. Identifying the indication is important not only to the caregivers but also to the patient who at times presents to our office with a request for an advertised drug that is inappropriate for the type of urinary incontinence
Randomized controlled trials and their design
Review of the voluminous pharmacologic studies for the treatment of urinary incontinence reveals several issues that need to be attended to when one undertakes an intensive randomized trial to establish the efficacy and safety of an agent (Table 1). First and foremost is the need for randomized controlled trials. Unquestionably, randomized controlled trials are considered to be the best approach in documenting the effectiveness and safety of a new agent or to determine the equivalence of 1
References (17)
- et al.
Preference, compliance and initial outcome of therapeutic options chosen by female patients with urinary incontinence
J Urol
(1995) - et al.
Overactive bladder: judging effective control and treatment study group. Prospective randomized controlled trial of extended- release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT Study
Mayo Clin Proc
(2001) - et al.
Tolterodine Study Group. Tolterodine once-dailysuperior efficacy and tolerability in the treatment of the overactive bladder
Urology
(2001) - et al.
Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans
J Urol
(1989) - et al.
Ephedrine in treatment of urinary incontinence
Urology
(1975) - et al.
Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
Obstet Gynecol
(1999) - et al.
The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction
Am J Obstet Gynecol
(1996) - et al.
Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence
J Urol
(2002)
Cited by (5)
Pharmacotherapy and incontinence
2013, Drug Therapy for the ElderlyTransdermal oxybutynin
2009, DrugsPhysiotherapy as a urinary incontinence treatment
2007, Ginekologia PraktycznaUrinary incontinence: Proper assessment and available treatment options
2005, Journal of Women's Health